In bone metastases from breast cancer, ERRα also improved anti-tumor immune responses [87] via the release of chemokines (CCL17, CCL20) and reduced synthesis of TGFβ3, allowing infiltration of cytotoxic CD8+ T cells and mitigating metastatic burden both in mice and humans, thus leaving the question open if agonism or antagonism of ERR is favorable for tumor patients. Here, CD8A is linked to neoplasm.